Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

Benzinga · 2d ago
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.